Evidence & Assurance
Lifestyle Compass is grounded in established evidence and guidance on cardiovascular prevention, personalised care and supported behaviour change.
Lifestyle Compass itself is an emerging implementation approach. Its feasibility, safety, acceptability and value will be tested rather than assumed.
EVIDENCE
DATA
EVALUATION
SAFETY
Our approach to evidence and assurance
Evidence informs the content
Lifestyle priorities and clinician prompts are grounded in relevant cardiovascular-prevention evidence and national guidance.
Decision logic is transparent & reviewable
The initial approach uses defined, reviewable rules rather than autonomous clinical decision-making.
Clinical boundaries are explicit
Lifestyle Compass supports prevention conversations.
Diagnosis, treatment and clinical responsibility remain within the existing provider pathway.
Evaluation precedes claims
Early evaluation will test delivery, usability, actionability and follow-through before claims are made about clinical or economic impact.
Why Lifestyle Compass is worth testing
The clinical importance of cardiovascular prevention is established. The opportunity is to deliver personalised action and follow-through more consistently within real services.
Personalised lifestyle support is already expected
National guidance recommends personalised lifestyle advice and support after ischaemic stroke or TIA. The NHS Health Check similarly requires cardiovascular risk to be communicated and followed by appropriate risk-reduction support.
Lifestyle Compass is designed to help services deliver these existing expectations more consistently.
Risk information alone is unlikely to be enough
A 2024 meta-analysis of 62 randomised trials found that cardiovascular-risk communication improved understanding of risk, but its effects on behaviour were more variable.
This is why Lifestyle Compass connects risk-relevant information with the person’s priorities, one achievable shared goal, confidence checking and appropriate support.
Follow-through is a recognised implementation gap
In the GENVASC evaluation of the NHS Health Check, around one-third of people identified as being at high cardiovascular risk had no recorded follow-up or treatment.
NHS economic modelling also suggests that better follow-up could materially increase the value of the Health Check programme. These findings support testing a more structured approach; they do not establish an effect or return on investment for Lifestyle Compass.
Clear scope and clinical boundaries
Lifestyle Compass supports
-
structured lifestyle assessment
-
personalised patient and clinician summaries
-
identification of relevant prevention priorities
-
shared goal-setting
-
local signposting
-
planned follow-up where commissioned
-
measurement of delivery and feasibility
The provider pathway retains responsibility for
-
diagnosis and investigation
-
acute symptoms and clinical urgency
-
interpretation of clinical measurements
-
prescribing and medication changes
-
abnormal findings and escalation
-
the authoritative clinical record
-
overall clinical care
Lifestyle Compass supports the prevention conversation. It does not create a parallel clinical record or act as a diagnostic, triage or autonomous treatment system.
Safe development and proportionate evaluation
The current demonstrators store no patient data and are not live clinical services. A feasibility pilot would proceed only after the required pathway, data, governance, clinical-safety and technical arrangements had been agreed with the host organisation.
Before live deployment
The implementation-design phase would define:
​
-
the minimum necessary dataset
-
lawful basis and data responsibilities
-
access, retention and deletion
-
the Data Protection Impact Assessment
-
clinical hazards and controls
-
relevant DTAC and clinical-safety requirements
-
staff training and operational support
-
the evaluation protocol and go/no-go criteria
What the pilot would test
The feasibility pilot would test
​
-
completion and engagement
-
patient and practitioner acceptability;
-
assessment and consultation time;
-
usefulness of the personalised outputs;
-
whether priorities and goals are recorded;
-
signposting and early follow-through;
-
differences in reach and engagement;
-
implementation effort and delivery cost.
The initial evaluation would not establish reductions in cardiovascular events, hospital admissions, health inequalities or NHS costs. Claims about clinical effectiveness and cost-effectiveness would require further evaluation.
Aligned with National Direction
​​
Lifestyle Compass is designed to help operationalise established expectations for personalised prevention, shared decision-making, appropriate support, pathway integration and measurable delivery.
​
Its development aligns with NICE cardiovascular-risk guidance, the National Clinical Guideline for Stroke, the NHS model of personalised care, the NHS Health Check review and current NHS priorities for evidence-led pathway improvement and evaluation.
View selected evidence & guidance: - NICE NG238: cardiovascular risk assessment and reduction - National Clinical Guideline for Stroke, 2023 - Bakhit et al., cardiovascular-risk communication meta-analysis, 2024 - GENVASC NHS Health Check evaluation, 2023 - OHID NHS Health Check review - NHS England cardiovascular high-impact interventions - NHS personalised-care model - NHS digital clinical-safety and DTAC guidance